A Discussion About a Hematology Career in Industry With Drs. Benjamin Kim and Mark Chao
Dr. Benjamin Kim and Dr. Mark Chao discuss what it's like for a hematologist holding an industry position.
Predicting Responses to Gemtuzumab Ozogamicin
Dr. Raetz looks at the use of gemtuzumab ozogamicin (CO) for the treatment of acute myeloid leukemia in adults and children.
Dr. Abdel-Wahab discusses the use of vitamin C to restore TET2 deficiency in combination with PARP inhibition in the treatment of leukemia.
Dr. Abdel-Wahab and Dr. Taylor look at a study that evaluates the safety of combining the anti-PD-L1 antibody atezolizumab with the novel hypomethylating agent guadecitabine in older adults with AML not eligible for standard induction therapy.
Dr. Abdel-Wahab provides an overview of histiocytoses or histiocytic neoplasms, some of the most challenging hematologic disorders to diagnose and categorize.
Dr. Abdel-Wahab discusses the effects of SAMHD1 depletion on the response to multiple chemotherapeutic agents.
Dr. Abdel-Wahab studies the role of the epitranscriptome in the context of normal and malignant hematopoiesis.
Dr. Abdel-Wahab and Dr. Taylor review the progress made during 2016 in understanding the molecular underpinnings of acute myeloid leukemia (AML) as well as in the use of precision medicine for patients with AML.
Dr. Abdel-Wahab and Dr. Taylor study the biology of mutant IDH1 in a myeloid-specific context with the additive effect of aging, and highlight one of the TET2-independent consequences of 2HG.
Dr. Abdel-Wahab and Dr. Taylor cover a study that measures the safety of combination ABT-199 and hypomethylating agents in older adults with acute myelogenous leukemia (AML), who are treatment-naive and not eligible for standard induction therapy.
Drs. Abdel-Wahab and Taylor look at a study about the use of core circadian clock genes in anti-leukemic therapy.
Dr. Abdel-Wahab and Dr. Taylor shed light on two recent studies that have identified synthetic lethal interactions created by deletion of genes in the neighboring genome around the 9p21 locus. Deletion of the 9p21 locus is one of the most common genetic events in cancer, yet there is no therapy that targets cancer cells with this alteration.
November-December 2017Volume 14, Issue 6
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology